Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,570.01% | 143.89% | 117.64% | 105.21% | 101.52% |
| Total Depreciation and Amortization | -6.88% | -15.03% | -11.33% | -8.28% | -1.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 270.98% | -49.57% | -53.35% | -66.87% | -88.32% |
| Change in Net Operating Assets | 1.89% | -48.95% | -94.12% | -212.65% | -445.28% |
| Cash from Operations | -2.52% | 58.92% | 34.57% | 18.91% | -23.09% |
| Capital Expenditure | -49.56% | -79.95% | -81.32% | -153.10% | -185.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 182.13% | 1,095.04% | 269.05% | -124.41% | 165.27% |
| Cash from Investing | 506.38% | 555.70% | 20.44% | -212.04% | 116.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 61.12% | 55.18% | 28.30% | 35.48% | -14.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -38.52% | -100.00% | 100.00% | 100.00% |
| Cash from Financing | 153.89% | -0.16% | -41.89% | -76.28% | -86.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.37% | 224.51% | 29.99% | -2,828.14% | -26.92% |